CH 19 - Degenerative Changes in Aging

Aging and Senescence

  • Senescence
    • Defined as the progressive, intrinsic process of deterioration associated with advancing age.
    • Distinct from life‐span; focuses on quality and function rather than mere chronology.
  • Life expectancy
    • Statistical measure of average years a person is expected to live.
    • Continues to rise due to medical and public-health advances, yet senescent decline still occurs.

Theories of Aging

  • Developmental (Genetically Programmed) Theories
    • Aging results from predetermined genetic timelines.
    • Examples: telomere attrition, neuroendocrine clock changes.
  • Accumulated Mutation Theory
    • Somatic mutations accrue over time causing functional loss.
  • Immunologic Theory
    • Gradual deterioration of the immune system; reduced self–non-self discrimination → autoimmunity.
  • Antagonistic Pleiotropy
    • Genes beneficial early in life exert harmful effects later (e.g., high sex hormones → later cancer risk).
  • Neuroendocrine Theory
    • Dysregulation of the HPA axis, reduced hormone pulsatility, and receptor sensitivity accelerate decline.
  • Stochastic (Error) Theories
    • Free Radical / Oxidative Stress: Accumulation of O_2^-, OH\cdot, lipid peroxides damage DNA, lipids, proteins.
    • Somatic Mutation: Random DNA replication/repair errors interfere with cell function.

General Manifestations of Aging

  • ↑ Mortality rates across populations.
  • Changes in biochemical tissue composition (↓ water, altered collagen cross-linkage).
  • Progressive ↓ in physiologic reserve (cardiac output, GFR, vital lung capacity).
  • Lowered adaptive responses to environmental stresses (temperature, toxins, infection).
  • Greater vulnerability + susceptibility to acute & chronic diseases.

Manifestations of Aging – Systemic Overview

  • Altered nutrition & metabolic processes (obesity or undernutrition).
  • Altered elimination (renal & gastrointestinal).
  • Altered perfusion (cardiovascular, pulmonary).
  • Fluid/electrolyte imbalances.
  • Impaired mobility & musculoskeletal integrity.
  • Impaired immune response (immune senescence).
  • Proliferative changes (myeloproliferative disorders, cancer risk).
  • Cellular changes underpin many of the above.

Cellular Changes

  • Atrophy: reduction in cell size → organ shrinkage.
  • Hypertrophy: compensatory cellular enlargement (e.g., left ventricular wall).
  • Impaired mitosis: slower tissue regeneration.
  • Lipid deposition + lipofuscin accumulation ("wear-and-tear" pigment).
  • Oxidative damage from free radicals.
  • Build-up of metabolic waste products (advanced glycation end products, AGEs).

Appearance Changes

  • Skin: ↑ dryness, wrinkles, mottled pigmentation, ↓ elasticity (elastin/collagen deterioration).
  • Hair: diffuse loss (alopecia), graying due to ↓ melanocyte activity.

Fluid & Electrolyte Balance

  • ↓ Total body water → ↑ risk of dehydration & electrolyte shifts.
  • Body‐mass redistribution (↓ lean mass, ↑ fat → altered drug volumes).
  • Renal aging compromises sodium/water regulation.

Immune Response & Immunosenescence

  • Reduced antigenic response; diminished naïve T-lymphocyte output (thymic involution).
  • ↓ IgE-mediated hypersensitivity; ↑ prevalence of allergies can paradoxically fall.
  • Enhanced autoimmunity (e.g., rheumatoid arthritis prevalence).
  • Delayed wound healing due to impaired inflammatory and proliferative phases.

Proliferative Changes & Cancer Risk

  • Chronic myeloproliferative disorders:
    • Polycythemia vera
    • Primary thrombocythemia
  • Cancer incidence rises because of:
    • Cumulative genetic mutations
    • Impaired immune surveillance
    • Longer carcinogen exposures
    • Diminished DNA repair mechanisms

Neurologic Function Changes

  • Cognition: slower processing, memory retrieval challenges.
  • Sensation: decreased proprioception, smell, and taste acuity.
  • Pain: altered thresholds; may mask acute pathology.
  • Motor: slower reflexes, fine-motor coordination decline.

Mobility & Musculoskeletal Degeneration

  • Osteopenia → Osteoporosis: ↓ bone mineral density (BMD).
  • Kyphosis: anterior vertebral collapse.
  • Chondrocalcinosis: calcium pyrophosphate deposition in cartilage.
  • Sarcopenia: loss of lean skeletal-muscle mass and strength.

Perfusion & Cardiopulmonary Changes

  • Vascular smooth-muscle stiffness → ↓ elasticity → ↑ afterload.
  • Compensatory left-ventricular hypertrophy.
  • Progressive atherosclerosis.
  • ↓ Pulmonary capillary density → limited O_2 uptake.

Metabolic Process Alterations

  • Mineral metabolism: Ca^{2+}, PO_4^{3-}, Mg^{2+} dysbalance.
  • Trace vitamin/element handling changes (Vit D, B_{12}, folate, iron).
  • Acid–base homeostasis less efficient (renal & respiratory buffering decline).
  • Macronutrient metabolism: risks for both obesity (↓ activity) and undernutrition (anorexia of aging).
  • Endocrine: diminished thyroid, parathyroid, adrenal, pituitary, gonadal output.

Vitamin D & Calcium Homeostasis (Key Pathway)

  • Skin: UV light converts 7-dehydrocholesterol → Vitamin D_3.
  • Liver: Vitamin D-25-hydroxylase → 25(OH)D (calcidiol).
  • Kidney: 1\alpha-hydroxylase (stimulated by PTH) → 1,25(OH)_2D (calcitriol).
  • Physiologic outcomes:
    • ↑ Ca^{2+} intestinal absorption.
    • ↑ Renal Ca^{2+} reabsorption.
    • ↑ Bone remodeling & mineralization.

Nutrition in Aging

  • Common deficiencies: protein, calories, Vit D, Ca, B vitamins, iron, zinc.
  • Consequences: cognitive impairment, infection risk ↑, anemia, impaired wound healing.

Elimination Changes

Renal/Urinary

  • ↓ Renal blood flow & glomerular filtration rate (GFR).
  • ↓ Nephron number & mass; impaired proximal‐tubular function.
  • Lower renin & aldosterone → salt/water balance issues.
  • ↓ Drug clearance → polypharmacy toxicity.
  • Urinary incontinence prevalence ↑.

Gastrointestinal

  • Constipation (slower transit, ↓ fiber/water, medications).
  • Diarrhea episodes (malabsorption, infections).
  • Fecal incontinence & impaction in severe cases.

Management & Screening of Degenerative Changes

  • Primary Prevention: vaccines, fall prevention, exercise, nutrition.
  • Screening: assess comorbidities, physical/cognitive function, ADLs, IADLs, social supports.
  • Goal: maintain independence, reduce morbidity.

Exemplary Degenerative Disorders

Hutchinson–Gilford Progeria Syndrome (HGPS)

  • Pathophysiology
    • Extremely rare accelerated-aging disorder (≈1/18 million births).
    • Autosomal dominant/recessive LMNA gene mutations → abnormal lamin A ("progerin").
    • Advanced paternal age = major risk factor.
    • Systems affected: skin, musculoskeletal, cardiovascular.
  • Clinical Manifestations (first year of life)
    • Alopecia, prominent scalp veins, sclerodermatous skin, lipodystrophy, growth failure.
    • Delayed dentition, high‐pitched voice, hearing loss, skeletal dysplasia, incomplete puberty.
  • Diagnosis
    • History + physical; elevated plasma hyaluronic acid; radiologic evidence of osteolysis.
  • Treatment
    • No approved cure.
    • Investigational: gene editing, farnesyltransferase inhibitors, antisense therapy.
    • Supportive: nutrition, physiotherapy for mobility, vascular monitoring, psychosocial family support.

Osteoporosis

  • Pathophysiology
    • Bone-remodeling imbalance: osteoclastic resorption > osteoblastic formation.
    • Primary (post-menopausal, senile) vs Secondary (endocrine, medication, genetic).
    • Risk factors: family history, estrogen loss, age, low Ca/Vit D, smoking, alcohol, inactivity.
  • Clinical Manifestations
    • Fragility fractures (hip, vertebral compression).
    • Vertebral trabecular loss, cortical thinning → height loss, kyphosis.
  • Bone-Remodeling Cycle
    • \text{Resorption (30–40 d)} → \text{Reversal} → \text{Formation (120 d)}.
  • Diagnosis
    • DEXA scan: T\text{ score }= -1.0\text{ to }-2.5 (osteopenia); < -2.5 (osteoporosis).
    • Z score for age-matched comparison; quantitative ultrasound adjunct.
  • Prevention
    • Adequate Ca (≈1 200 mg/d) & Vit D (≈800 IU/d).
    • Weight-bearing exercise, smoking/alcohol cessation.
    • Early BMD screening & risk-based pharmacotherapy.
  • Treatment
    • Ca/Vit D supplementation.
    • Antiresorptives: bisphosphonates, calcitonin, selective estrogen-receptor modulators (SERMs), hormone therapy.
    • Anabolic drugs (teriparatide) for severe disease.

Alzheimer Disease (AD)

  • Pathophysiology
    • Progressive neurodegenerative disorder characterized by:
    • Neurofibrillary tangles formed by hyper-phosphorylated tau protein.
    • Senile (amyloid) plaques composed of \beta-amyloid (Aβ) peptides.
    • Chronic neuro-inflammation & oxidative injury → neuronal atrophy.
    • Multifactorial: genetic (APOE-ε4, presenilin) + environmental factors.
  • Clinical Manifestations
    • Global cognitive decline, behavioral changes, gradual functional loss.
    • 7-stage progression (early memory loss → severe dementia, dependence).
    • Early signs: forgetfulness, confusion, restlessness, mood swings, visuospatial deficits.
  • Diagnosis
    • Comprehensive history & physical; neurologic & mental-status testing (MMSE, MoCA).
    • Imaging (CT, MRI, PET) to exclude other causes; definitive confirmation at autopsy.
  • Treatment
    • Symptom management & quality-of-life maximization.
    • Pharmacology: centrally acting cholinesterase inhibitors (donepezil), NMDA antagonists, antidepressants, antipsychotics as needed.
    • Supportive: caregiver support, safety modifications, cognitive stimulation.

Ethical, Practical & Public-Health Implications

  • Rising aging population → health-care resource strain.
  • Importance of preventive strategies (osteoporosis screening, dementia early detection).
  • Ethical considerations: autonomy vs. safety, end-of-life planning, equitable access.
  • Social determinants (nutrition, housing, social support) modulate aging trajectory.

Key Numerical & Statistical References

  • DEXA T-score thresholds: -1.0 \le T < -2.5 = osteopenia; T < -2.5 = osteoporosis.
  • Bone remodeling timelines: Resorption ≈ 30–40 days; Formation ≈ 120 days.
  • HGPS incidence: ~1 per 18 million births.

Real-World Connections & Preventive Actions

  • Vitamin D fortification & sun-exposure guidelines address widespread deficiency.
  • Community fall-prevention programs lower fracture-related morbidity.
  • Cognitive-training apps & social engagement mitigate Alzheimer risk.
  • Policy: promote age-friendly environments, universal design housing.

Study Tips & Integration

  • Relate aging theories to observed clinical changes (e.g., oxidative stress ↔ skin wrinkles).
  • Memorize vitamin D pathway—commonly tested.
  • Recognize fracture patterns that suggest osteoporosis (hip & vertebrae).
  • For Alzheimer disease, link pathology (tangles & plaques) to symptoms (memory, visuospatial).